A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma

Digestive and Liver Disease

Volumn 43, Issue 12, 2011, Pages 1015-1021

  Brandi, Giovanni ^a   Biasco, Guido ^a   Mirarchi, Maria Grazia ^a   Golfieri, Rita ^a   Di Paolo, Antonello ^b   Borghi, Alberto ^a   Fanello, Silvia ^a   Derenzini, Enrico ^a   Agostini, Valentina ^a   Giampalma, Emanuela ^a   Cappelli, Alberta ^a   Pini, Patrizia ^a   Costantini, Sarah ^a   Danesi, Romano ^b   Bolondi, Luigi ^a   Piscaglia, Fabio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Adverse event; Chemotherapy; Cirrhosis; Hepatic artery infusion; Hepatocellular carcinoma; Pharmacokinetic

Indexed keywords

IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTERITIS; ARTICLE; ASTHENIA; CANCER PATIENT; CATHETER COMPLICATION; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; FEMALE; HEPATIC ARTERY; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER ISCHEMIA; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SEPSIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, HEPATOCELLULAR; CATHETERIZATION; DIARRHEA; DISEASE-FREE SURVIVAL; FEMALE; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 80055090934     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2011.08.005     Document Type: Article

References (27)

1. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
2. Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37:429-442.
3. Llovet J.M., Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008, 48:S20-S37.
4. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
5. Chabot G.G. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 1997, 33:245-259.
6. Fiorentini G., Rossi S., Dentico P., et al. Irinotecan hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: a phase II clinical study. Tumori 2003, 89:382-384.
7. Rothenberg M.L., Blanke C.D. Topoisomerase I inhibitors in the treatment of colorectal cancer. Semin Oncol 1999, 26:632-639.
8. Matsuoka H., Yano K., Seo Y., et al. Cytotoxicity of CPT-11 for gastrointestinal cancer cells cultured on fixed-contact-sensitive plates. Anticancer Drugs 1995, 6:413-418.
9. Gornet J.M., Azoulay D., Duclos-Vallee J.C., et al. Complete remission of unresectable hepatocellular carcinoma on healthy liver by the combination of aggressive surgery and high-dose-intensity chemotherapy by CPT-11. Anticancer Drugs 2000, 11:649-652.
10. O'Reilly E.M., Stuart K.E., Sanz-Altamira P.M., et al. A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer 2001, 91:101-105.
11. Boige V., Taïeb J., Hebbar M., et al. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. Eur J Cancer 2006, 42:456-459.
12. Grosso M., Scarrone A., Pedrazzini F., et al. Intra-arterial hepatic chemotherapy: management of liver tumors by percutaneous port-a-cath positioning. J Exp Clin Cancer Res 2003, 22:171-175.
13. Suto K., Sakada Y., Tanaka M., et al. Phase I study of 24hr continuous hepatic arterial infusion of irinotecan (24hr HAI CPT-11) for metastatic/primary liver cancer. 27th European society of medical oncology meeting 2002 2002.
14. Llovet J.M., Bru C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19:329-338.
15. Raymond E., Boige V., Faivre S., et al. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol 2002, 20:4303-4312.
16. van Riel J.M., van Groeningen C.J., Kedde M.A., et al. Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. Clin Cancer Res 2002, 8:405-412.
17. Falcone A., Di Paolo A., Masi G., et al. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. J Clin Oncol 2001, 19:3456-3462.
18. Masi G., Falcone A., Di Paolo A., et al. A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. Clin Cancer Res 2004, 10:1657-1663.
19. Gupta E., Vyas V., Ahmed F., et al. Pharmacokinetics of orally administered camptothecins. Ann NY Acad Sci 2000, 922:195-204.
20. Takimoto C.H., Morrison G., Harold N., et al. Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients. J Clin Oncol 2000, 18:659-667.
21. Xie R., Mathijssen R.H., Sparreboom A., et al. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther 2002, 72:265-275.
22. Brandi G., de Rosa F., Biasco G. Irinotecan toxicity: genes or intestinal microflora?. Br J Cancer 2009, 100:1017.
23. van Groeningen C.J., Van der Vijgh W.J., Baars J.J., et al. Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: a need for guidelines. Clin Cancer Res 2000, 6:1342-1346.
24. Takasuna K., Hagiwara T., Hirohashi M., et al. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996, 56:3752-3757.
25. Barnett K.T., Malafa M.P. Complications of hepatic artery infusion: a review of 4580 reported cases. Int J Gastrointest Cancer 2001, 30:147-160.
26. Arai K., Kitamura M., Miyashita K., et al. Bile duct necrosis and hepatic necrosis following hepatic arterial infusion chemotherapy. Gan To Kagaku Ryoho 1991, 18:1856-1859.
27. Ohtsubo K., Watanabe H., Tsuchiyama T., et al. Advanced hepatocellular carcinoma treated effectively with irinotecan via hepatic arterial infusion followed by proton beam therapy. J Infect Chemother 2009, 15:316-321.